The objective of this study was to confirm the effects of curcumin and to investigate the effects of its combination with a reduced dose of rosuvastatin in an adenine-induced model of chronic kidney disease (CKD) and associated dyslipidemia in rats. Renal function and morphology, as well as lipid status, were assessed using laboratory parameters and histopathological analysis. Male Wistar rats (n=36) randomly divided into six groups, were treated for 24 days: normal control (standard diet), CKD control (adenine diet, 0.75% w/w adenine-supplemented diet), curcumin (100 mg/kg/day + adenine diet), rosuvastatin minimal therapeutic dose (MTD) (5 mg/day + adenine diet), rosuvastatin reduced dose (RD, 25% of rosuvastatin MTD + adenine diet), and rosuvastatin RD + curcumin (25% of rosuvastatin MTD + curcumin 100 mg/kg/day + adenine diet) group. While rosuvastatin alone showed only antilipemic action, both curcumin alone and its combination with a reduced dose of rosuvastatin showed better renal protection with lower serum creatinine levels and milder renal morphological alterations, as well as better antilipemic action with lower levels of triglycerides, very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) cholesterols compared with the levels in CKD control rats. Treatment with curcumin alone also resulted in a significantly higher estimated glomerular filtration rate, lower uric acid levels, and higher high-density lipoprotein (HDL) cholesterol, while the combined therapy additionally resulted in higher serum albumin levels, lower total cholesterol, and both atherogenic and coronary risk indexes compared with CKD control rats. The results of this study confirmed the beneficial effects of curcumin alone and provided new evidence for the beneficial effects of its combination with a reduced dose of rosuvastatin in rats with CKD and associated dyslipidemia.

Introduction: Meningiomas are the most common benign tumor of the central nervous system, accounting for 53.3% and 37.6% of all central nervous system tumors (1). The World Health Organization (WHO) Grade I meningiomas account for 80.5% of all meningiomas and are considered benign meningiomas; the WHO Grade II meningiomas account for 17.7% of all meningiomas and exhibit more aggressive behavior. Methods: In the period 2015-2022, a retrospective single-center study at the clinic of neurosurgery at the Clinical Center University of Sarajevo was conducted, which included patients with a pathohistological finding of WHO Grade I or II meningioma. Depending on the pathohistological grade of the tumor, patients were divided into two groups: Grade I and Grade II patients. Patients were examined clinically and radiologically. Clinical data collected included in the study: Gender, age, number of symptoms before surgery, whether patients were symptomatic or asymptomatic, pre-operative Eastern Cooperative Oncology Group,and Karnopsky performance scale. Pre-operative contrast magnetic resonance imaging of the head measured tumor volume, temporal muscle thickness (TMT), sagittal midline shift, and surrounding cerebral edema. Results: A total of 80 patients were enrolled in the study, 68 with WHO Grade I and 12 with WHO Grade II meningiomas. We found that patients with Grade I meningioma were younger and that the mean thickness of the temporal muscle was statistically thicker than in patients with Grade II. Increasing TMT was significantly and positively associated with Grade I tumors and negatively associated with Grade II tumors (p = 0.032). Conclusion: This study demonstrates that TMT can serve as a radiologic pre-operative indicator of meningioma grade and provide valuable guidance to neurosurgeons in surgical planning. Further studies are needed to validate these results.

Background/Aim:Dental age estimation in adults is a challenging process due to the lack of sufficient information on the accuracy of dental methods applied in the identification of persons without information on identity. Previous studies on dental age estimation in adults suggested that each method should be tested on a population other than one which was used to develop the specific method. The aim of this study was to estimate dental age in adults from Bosnia and Herzegovina with the radiographic analysis of the pulp/tooth ratio of lower canines and to determine differences from chronological age. Material and Methods: The sample for the research comprised 50 periapical radiographs, with visible intact lower canine teeth, derived from an archive of the Department of Dental Morphology, Dental Anthropology and Forensics. After the selection process, all radiographs were digitalized. Additional information used is the chronological age and sex of the person to whom the images belonged. The measurements of the pulp space and the lower canine tooth were performed using the ImageJ computer methods. The results of measurements were entered in formulas for assessments of dental age, as per equations given by the authors. Results: The research has shown that there is a significant difference in examined population between the dental age estimated by the analysis of pulp/tooth ratio of lower canine teeth and the chronological age. The standard error of regression for Cameriere model was 14.12 years, and this model proved to be statistically significant (p= 0.0017). Kvaal-Solheim model from 1994 has shown a standard error of 15.07 years, and did not prove to be statistically significant (p= 0.054), while another model from 1995, by the same authors, shows a standard error of 14.64 years, and it proved to be statistically significant (p= 0.011). Conclusions: It is possible to estimate dental age by means of pulp/tooth ratio. However, it is necessary to conduct further research that will include a larger number of examinees and different age groups and also consider the specificity of teeth in Bosnia - Herzegovina's population to acquire more accurate data on accuracy and reliability of those methods in this population.

Introduction: Newborn screening (NBS) is a system of organized search in the entire neonatal population for specific diseases. In Bosnia and Herzegovina, two diseases are included in NBS, congenital hypothyroidism (CH), and phenylketonuria. The screening for CH is based on determination of thyroid stimulating hormone (TSH) levels in blood obtained by heel prick method. The aim of this study is to evaluate the effectiveness of NBS program for CH based on TSH and establish the mean age of diagnosis of CH.Methods: TSH was measured by time-resolved fluoroimmunoassay (DELFIA Neonatal hTSH kit). The TSH cutoff value was 9 μU/mL. Neonates with TSH < 9 μU/mL had a negative NBS result. Neonates with TSH ≥ 9 μU/mL were recalled for a confirmation test and thyroid hormones were determined from venous blood to establish diagnosis of CH.Results: A total of 24,351 neonates were subjected to NBS in our institution. A total of 164 newborns with TSH ≥ 9 μU/ml were sent to additional testing (mean recall rate of 0.68%) at a mean age of 11.4 ± 0.5 days of life. In this group, diagnosis of CH was confirmed in 22 neonates (13.41%). The mean rate of false positive results of NBS was 0.59%. The incidence of CH in Sarajevo Canton ranged from 1/2477 in 2018 to 1/641 in 2020. The mean incidence of CH over a 5-year period was 1/1085, while the mean age at the time of diagnosis was 16.5 ± 1.2 days.Conclusion: The analysis of NBS on congenital hypothyroidism data showed the satisfactory recall and false positive rate and indicated well selected TSH cutoff value. The mean age at the time of diagnosis assures early treatment and good neurological outcome in neonates with CH.

Objectives: The aim of this study was to investigate the effects of carvedilol treatment through improvement of New York Heart Association (NYHA) class, ejection fraction (EF) and blood pressure (BP) values in patients with chronic heart failure (CHF). Methods: This multicenter, observational, non-interventional was conducted in 25 medical centers in Bosnia and Herzegovina, from April 2015 until December 2015 (nine months). It included 167 patients of both genders, older than 50 years, who were diagnosed with CHF according to the NYHA classification and had EF <50%. The patients were administered carvedilol tablets and were followed during six visits: baseline and five follow-ups, over the period of 24 weeks. Results: At the beginning of the study, CHF NYHA class I was present in 5 (3.0%) patients, NYHA class II in 76 (45.5%) and NYHA class III in 66 (39.5%) patients. After 24 weeks, CHF NYHA class I was present in 43 (25.7%) patients, NYHA class II in 75 (44.9%) and NYHA class III in 21 (12.6%) patients. There is a statistically significant change of NYHA class before and after 24 weeks of treatment with carvedilol (rho=0.272; p=0.002). At the baseline observation, mean value of EF was 43.06±9.6%. after 24 weeks of treatment, the mean value of EF increased to 48.15±10.51% (p=0.0001). Average increase of EF after the treatment was 5%, or ranging from 1.5-7.5%. Systolic and diastolic blood pressure significantly decreased from baseline to final observation (-15.4 mmHg and -9.18 mmHg; p=0.0001). Conclusion: Carvedilol is effective in improvement of NYHA class and ejection fraction as well as in reduction of high blood pressure in patients with congestive heart failure. Keywords: chronic heart failure, NYHA classification, carvedilol, treatment efficacy